Yüklüyor......
PARP inhibitor re-sensitizes Adriamycin resistant leukemia cells through DNA damage and apoptosis
Resistance to Adriamycin (ADR) is an increasing problem in the treatment of leukemia and the development of novel therapeutic strategies is becoming increasingly important. Olaparib is a poly (adenosine diphosphate-ribose) polymerase (PARP) 1 inhibitor, which has promising antitumor activity in pati...
Kaydedildi:
| Yayımlandı: | Mol Med Rep |
|---|---|
| Asıl Yazarlar: | , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
D.A. Spandidos
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6297734/ https://ncbi.nlm.nih.gov/pubmed/30431088 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mmr.2018.9628 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|